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 Eight fl uorinated nanoparticles (NPs) are synthesized, loaded with doxo-
rubicin (DOX), and evaluated as theranostic delivery platforms to breast 
cancer cells. The multifunctional NPs are formed by self-assembly of either 
linear or star-shaped amphiphilic block copolymers, with fl uorinated seg-
ments incorporated in the hydrophilic corona of the carrier. The sizes of the 
NPs confi rm that small circular NPs are formed. The release kinetics data 
of the particles reveals clear hydrophobic core dependence, with longer 
sustained release from particles with larger hydrophobic cores, suggesting 
that the DOX release from these carriers can be tailored. Viability assays 
and fl ow cytometry evaluation of the ratios of apoptosis/necrosis indicate 
that the materials are non-toxic to breast cancer cells before DOX loading; 
however, they are very effi cient, similar to free DOX, at killing cancer cells 
after drug encapsulation. Both fl ow cytometry and confocal microscopy 
confi rm the cellular uptake of NPs and DOX-NPs into breast cancer cells, 
and in vitro  19 F-MRI measurement shows that the fl uorinated NPs have 
strong imaging signals, qualifying them as a potential in vivo contrast agent 
for  19 F-MRI. 
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 Today, cancer is one of the leading causes 
of death in the industrialized world, 
becoming more prevalent with our longer 
life spans, making this an increasingly 
important research area. As the most 
common type of cancer among women, 
breast cancer has attracted signifi cant 
attention from scientists worldwide. Tradi-
tional treatments for breast cancer, such as 
chemotherapy, radiation, and surgery, have 
been effective in treating women over the 
last decades, but are associated with both 
discomfort and sometimes severe side 
effects for patients. 
 Doxorubicin (DOX), one of the most 
commonly used chemotherapeutics in the 
clinic, is employed to treat many different 
types of cancer, including bladder, lung, 
ovarian and breast cancer. [ 1–4 ] However, 
similar to many other anti-cancer drugs, 
DOX has severe issues with toxicity, 
and can cause cardiac damage. [ 5 ] Conse-quently, in the past few decades, several different nanoscale 
systems have been investigated as new delivery platforms for 
DOX in order to increase effi cacy and reduce side effects such 
as bystander tissue damage as well as to modify the pharma-
cokinetics of the pharmaceutical. Further, with nanoscale for-
mulation multi drug resistance (MDR) could be overcome, via 
control of the pharmacokinetics and biodistribution of the drug 
and alternative tumor uptake mechanisms. [ 6–13 ] By such sophis-
ticated nanomedical approaches to chemotherapy, advantageous 
synergistic effects in terms of enhanced drug solubility, tissue 
protection, drug circulation time, and selective drug accumula-
tion can be accomplished. [ 8,14 ] For this purpose, polymer plat-
forms have attracted substantial focus due to their engineered 
biocompatibility, biodegradability, and extensive versatility. [ 15–17 ] 
More recently, signifi cant focus has been directed towards the 
design of dual-functional delivery platforms, which provide 
both a therapeutic and a diagnostic function, so called theran-
ostics. [ 18,19 ] The advantages of such systems are complemen-
tary to the chemotherapeutic effect, in that theranostic systems 
can give simultaneous information regarding tumor hetero-
geneity, metastasis, and therapeutic effi cacy. [ 20,21 ] One popular 
approach to develop such theranostic entities is to combine the im 381wileyonlinelibrary.com
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 Figure 1.  Synthetic strategy to the theranostic NPs, where hydrophobic segments are visual-
ized in green and hydrophilic segments in blue. therapeutic delivery with an imaging modality, such as radionu-
clides for positron emission tomography (PET), computed tom-
ography (CT), or magnetic resonance imaging (MRI). [ 21 ] While 
PET and CT rely on radioactive nuclides and ionization radia-
tion, respectively, MRI is a non-invasive imaging technique that 
provides good visualization of soft tissue with good spatial reso-
lution. Further, its non-radioactive nature makes MRI suitable 
for use in treatment regiments that require multiple injections. 
Typically, chelates of paramagnetic compounds such as gado-
linium (Gd 3+ ) [ 22,23 ] and superparamagnetic iron-oxide nanopar-
ticles (SPIONs), [ 24–26 ] have been proposed as contrast agents 
for theranostic delivery. However, accumulation and toxicity of 
the Gd 3+ ion, due to release from its chelated form, and poten-
tial toxicity of SPIONs [ 27 ] may be an issue for theranostic pur-
poses. Recently, the use of the natural isotope  19 F has emerged 
as a promising alternative to these conventional paramagnetic 
agents for imaging. [ 28–35 ] Good biocompatibility and low back-
ground signal in vivo are attractive properties of the fl uorine 
atom, although relatively low sensitivity requires comparatively 
high concentrations for MRI applications. However, previous 
work has highlighted the importance of providing nanoparticle 
(NP) platforms that allow for high fl uorine content and mobility 
of the  19 F-atoms in order to provide benefi cial relaxation prop-
erties. [ 28 ] Further, very few reports have used fl uorinated poly-
mers to construct theranostic NPs using chemotherapeutics 
such as DOX. [ 29 ] Therefore, we herein present a versatile route 
to synthesize fl uorinated polymer NPs, which are detectable by 
 19 F-MRI, and able to encapsulate and deliver DOX, to combat 
breast cancer as a theranostic system. The characteristics of © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Wein2 wileyonlinelibrary.comthe NPs were established with conventional 
analytical techniques, and  19 F-NMR diffusion 
was used as a novel method to defi ne their 
size in complex media such as plasma. Fur-
thermore, the theranostic properties were 
evaluated by  19 F-MRI measurements and an 
array of cell-based assessments. 
 2 .  Results and Discussion 
 2.1 .  Synthesis and Characterization of Fluoro-
Containing Amphiphilic Polymers 
 In the present work, a facile method to pro-
duce fl uoro-containing polymer nanopar-
ticles (NPs) is presented, as schematically 
shown in  Figure  1 . Amphiphilic polymers 
with different hydrophobic segments and 
similar hydrophilic segments were spontane-
ously self-assembled to yield stable core-shell 
type NPs. By random introduction of fl uorine 
atoms along the hydrophilic segment of the 
polymer, NPs with very high fl uorine content 
have been realized, which thereby, facilitate 
high sensitivity  19 F-MRI phantom imaging. 
Simultaneously, the hydrophobic NP core 
allows for loading and protection of thera-
peutic cargos, thus rendering a versatile dual-functional theranostic delivery platform. 
 A library of amphiphilic polymers of different architec-
tures was synthesized in a two-step strategy. In the fi rst part, 
a number of different linear low molecular weight or low gen-
eration dendritic hydrophobic core molecules were designed 
and equipped with atom transfer radical polymerization 
(ATRP) initiating groups. The syntheses were conducted by 
employing standard base catalyzed esterifi cation reactions, 
described in the Supporting Information, and the structural 
integrity of the products was confi rmed by  1 H-NMR (Sup-
porting Information Figure S1). In the second part of the 
synthesis, the initiating moieties were utilized to polym-
erize hydrophilic statistical copolymers of the monomers 
oligo(ethylene glycol) methyl ether methacrylate (OEGMA 
(average  M n = 475)) and trifl uoroethyl methacrylate (TFEMA) 
via ATRP. In this manner, either linear or star-shaped (4 or 
16 arms) amphiphilic polymers were produced and subse-
quently characterized by  1 H-NMR and SEC analysis ( Table  1 
and Supporting Information Figure S2–S4). The fi rst part of 
the names in Table  1 denotes the hydrophobic segment of 
the polymer and the subscript number represents the total 
molecular weight of the amphiphilic polymer. TFEMA was 
chosen as the contrast agent due to its commercial availability 
as well as its chemically equivalent fl uorine atoms, which is 
optimal for NMR imaging since it results in no dilution of the 
NMR signal. OEGMA has emerged as a promising alternative 
to PEGylation, [ 36,37 ] and its hydrophilic and highly dynamic 
structure is hypothesized to facilitate the mobility of the fl uo-
rine atoms of TFEMA. heim Part. Part. Syst. Charact. 2013, 30, 381–390
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 Table 1.  Summary of the characteristics of the prepared polymers. 
 Polymer a)  Abbreviation Type OEGMA:TFEMA b)  F-content b) 
[wt%] 
 M n c) 
[g mol −1 ] 
 M n /arm c) 
[g mol −1 ] 
 Ð c)  
EBiB-P(OEGMA -co- TFEMA) EBiB-P(O -co- T) Linear 51:49 8.9 25 300 – 1.17 
Dodecanol-P(OEGMA -co- TFEMA) Dod-P(O -co- T) Linear 48:52 9.5 21 500 – 1.14 
Cholesterol-P(OEGMA -co- TFEMA) Chol-P(O -co- T) Linear 44:56 10.6 21 300 – 1.16 
diTMP-[G#0]-P(OEGMA -co- TFEMA) 10k [G#0]-P(O -co- T) 10k Star (4 arms) 49:51 8.8 10 300 2400 1.22 
diTMP-[G#0]-P(OEGMA -co- TFEMA) 28k [G#0]-P(O -co- T) 28k Star (4 arms) 50:50 8.6 27 900 6900 1.13 
diTMP-[G#2]-P(OEGMA -co- TFEMA) 23k [G#2]-P(O -co- T) 23k Star (16 arms) 44:56 4.4 22 500 1200 1.10 
diTMP-[G#2]-P(OEGMA -co- TFEMA) 36k [G#2]-P(O -co- T) 36k Star (16 arms) 47:53 5.4 36 000 2100 1.05 
diTMP-[G#2]-P(OEGMA -co- TFEMA) 52k [G#2]-P(O -co- T) 52k Star (16 arms) 49:51 6.2 52 000 3100 1.10 
 a) The fi rst part of the name denotes the hydrophobic segment of the polymer, and the subscript number represents the total molecular weight of the amphiphilic polymer; 
 b) H-NMR;  c) DMF-SEC. Ref. [38].  Following this procedure, three linear polymers with different 
hydrophobic core moieties were synthesized, with a comparable 
molecular weight of the hydrophilic segment, to determine the 
effect of the core on the NP characteristics and the drug release 
behavior. Additionally, fi ve star polymers were synthesized from 
either a [G#0] (4 arms) or [G#2] (16 arms) dendrimer core. In 
addition to the differences in the hydrophobic core size and 
number of hydrophilic arms of the [G#0] and [G#2] cores, the 
molecular weight of the hydrophilic segment was also varied to 
evaluate the possible impact of  M n on the material performance 
(Table  1 ). All polymerizations were conducted in acetone using 
a HMTETA/CuCl mediated system and proceeded in a con-
trolled manner with reproducible kinetics (Supporting Infor-
mation Figure S5). The reactions were monitored by  1 H-NMR 
and allowed to run to 30–50% conversion to obtain control 
over the fi nal products. All polymers typically show dispersities 
( Ð [ 38 ] of 1.1–1.2 as determined by SEC (Table  1 and Supporting 
Information Figure S6). Remaining trace amounts of copper 
in the polymers were removed by dialysis against an aqueous 
EDTA solution. By incorporation of fl uorinated monomers into 
the hydrophilic segments of the polymers, very high fl uorine 
content was accomplished, and similar monomer compositions 
of the hydrophilic segments (49–56 mol% of TFEMA) were 
achieved for all materials. Despite the high fl uorine content, © 2013 WILEY-VCH Verlag G
 Table 2.  Summary of NP sizes with and without DOX-loading, determined
  NPs 
   D h,v a) 
[nm] 
 D h b) 
[nm] 
EBiB-P(O -co- T) 5.9 ± 0.2 14 ± 4 
Dod-P(O -co- T) 6.3 ± 0.1 15 ± 3 
Chol-P(O -co- T) 6.9 ± 0.2 10 ± 3 
[G#0]-P(O -co- T) 10k 7.3 ± 0.6 9 ± 2 
[G#0]-P(O -co- T) 28k 6.8 ± 0.4 10 ± 2 
[G#2]-P(O -co- T) 23k 7.0 ± 0.1 10 ± 2 
[G#2]-P(O -co- T) 36k 7.1 ± 0.3 7 ± 1 
[G#2]-P(O -co- T) 52k 9.0 ± 0.2 8 ± 2 
 a) DLS (25 °C);  b)  TEM;  c) Fluorescent probe technique. 
Part. Part. Syst. Charact. 2013, 30, 381–390all materials are soluble in both water and phosphate buffered 
saline (PBS) up to concentrations of 15 mg mL −1 . High fl uorine 
content is of utmost importance to obtain a high signal in MRI 
since fl uorine atoms only have about 83% sensitivity compared 
to protons. [ 39,40 ] Additionally, during polymerization, it was dis-
covered that the reactivity of TFEMA is higher than of OEGMA. 
Consequently, the resulting polymers are expected to have a 
tapered composition with statistically more TFEMA closer to 
the core, and increasing amounts of OEGMA towards the chain 
ends. [ 41 ] 
 2.2 .  Nanoparticle Formation 
 Micellization of the polymers was conducted by fi rst dissolving 
them in dichloromethane (DCM), a good solvent for the hydro-
phobic core. Subsequently, PBS was slowly added to the solution 
and the DCM was evaporated during gentle stirring (100 rpm) 
for 36 h to form the core-shell particles. The synthesized poly-
mers readily formed micelles as observed by dynamic light 
scattering (DLS) and transmission electron microscopy (TEM) 
( Table  2 and Supporting Information Figure S1;  Figure  2 and 
Supporting Information Figure S7). DLS results show that all 
polymers self-assemble into relatively small NPs with diameters mbH & Co. KGaA, Weinheim 383wileyonlinelibrary.com
 by DLS and TEM. CMCs for the synthesized polymers in PBS solution. 
DOX-NPs   
 D h,v a) 
[nm] 
 D h b) 
[nm] 
CMC c) 
[ µ g mL −1 ] 
920 ± 50 10 ± 2 3.0 
1180 ± 200 11 ± 2 3.8 
860 ± 70 20 ± 3 2.2 
1100 ± 170 10 ± 2 1.8 
1030 ± 60 13 ± 4 1.8 
1030 ± 160 8 ± 2 1.1 
900 ± 110 16 ± 5 0.82 
1420 ± 140 9 ± 2 1.3 
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 Figure 2.  TEM images of NPs and DOX-NPs A) Chol-P(O -co- T) and B) DOX-Chol-P(O -co- T). 
Scale bar = 100 nm in both images. in the range of 6-9 nm in PBS. TEM confi rms that the particles 
formed are circularly shaped with a relatively narrow size distri-
bution, and NP sizes from TEM (7–15 nm) are generally larger 
than those observed by DLS (Table  2 ). The small NP sizes are 
in proximity to the reported threshold for renal clearance. [ 42 ] 
Furthermore, recent studies report the topologic nature of the 
polymer as an infl uencing factor. [ 43,44 ] It is possible that star-
shaped polymers may be benefi cial in this context since they 
have a more restricted reptation and therefore longer circula-
tion times. [ 43 ] The increase in size with increasing length of the 
hydrophilic segment of the [G#2]-core polymers is expected 
due to increased extension of the NP shell. However, the size 
decrease of the [G#0]-core polymers are more surprising. This 
may be an effect of the relatively large change in hydrophilic/
hydrophobic ratio of the [G#0] polymers, thus resulting in dif-
ferent aggregation numbers of the self-assembled structures. 
 To confi rm the applicability of the synthesized NPs for physi-
ological delivery, the stability of the NPs upon dilution is of sig-
nifi cant importance to avoid particle disassembly upon injection 
into the blood stream. Such instant disassembly may result in 
a burst release of the therapeutic cargo without any controlled 
release function. The critical micelle concentrations (CMCs) of 
the NPs were determined by employing the pyrene probe tech-
nique using fl uorescence spectroscopy (Table  2 and Supporting 
Information Figure S8). [ 45 ] All polymers show very low CMCs 
(0.8-3.8  μ g mL −1 ), thus confi rming their NP stability upon dilu-
tion. Further, the lower CMC values for the star-shaped polymers 
suggests that they are more prone to form NPs, possibly with a 
lower aggregation number than the linear polymers. However, 
the star polymers still show an assembly behavior, which indi-
cates that they do no not form discrete unimolecular NPs. 
 2.3 .  19 F-NMR and  19 F-NMR Diffusion Studies of NPs in 
Complex Media 
 Three of the synthesized NPs; EBiB-P(O -co- T), Chol-P(O -co- T), 
and [G#0]-P(O -co- T) 28k , were chosen as model compounds to 
be evaluated with respect to their relaxation behavior (a repre-
sentative  19 F-NMR is reported in Supporting Information Figure 
S9). The relaxation parameters ( T 1 and  T 2 ) of the NPs were © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Wein84 wileyonlinelibrary.commeasured employing a 600 MHz NMR 
instrument, and are reported in Table S4 
(Supporting Information). As expected, all  T 1 
and  T 2 relaxations are very similar, thus indi-
cating that the chemical surroundings of the 
fl uorine atoms in the different NPs, regard-
less of the architecture of the hydrophobic 
core, are fairly equal. Furthermore, the bene-
fi cially short  T 1 relaxation time (compared to 
low  M w compounds) of approximately 320 ms 
for all materials is most likely a consequence 
of linking the fl uorine-containing monomers 
to a high molecular weight polymer.  T 2 relaxa-
tion times are somewhat lower than expected 
(5–8 ms), thus indicating that the mobility of 
the fl uorine atoms in the dynamic OEGMA 
segments is not as high as anticipated. 
 The fact that fl uorine is covalently incor-
porated in the NP structure results in a unique possibility to 
characterize NP sizes in plasma-containing media, and inves-
tigate the effect of proteins on the size of the NPs. Although, it 
is widely accepted that PEGylation of NPs results in prolonged 
circulation time in vivo, there are, to the authors’ best knowl-
edge, few studies that report the determination of NP sizes in 
plasma. [ 46 ] Therefore, we hereby report  19 F-NMR diffusion as 
a novel and attractive approach to determine the size of fl uori-
nated NPs in complex media. Due to the unique fl uorine signal 
from our NPs,  19 F-NMR diffusion can be employed to deter-
mine the size of the NPs in protein rich media as Dulbecco’s 
modifi ed Eagle medium (DMEM) with fetal bovine serum 
(FBS), and even in plasma without any measurement inter-
ferences. Table S4 (Supporting Information) presents the NP 
sizes of the three model polymers in PBS, DMEM, and plasma 
measured by  19 F-NMR diffusion. All NPs have somewhat 
smaller sizes when determined by  19 F-NMR diffusion com-
pared to DLS, which is expected since NMR diffusion is known 
to overestimate smaller objects rather than larger objects as is 
the case with DLS. Furthermore, the NP sizes from  19 F-NMR 
in different media indicate that increasing the complexity 
of the surroundings decreases the diameter of the NPs. This 
could be an effect of reduced solubility of the polymers (due to 
changes in ionic strength, salt types and concentrations or pro-
tein content), thus causing the NPs to shrink, suggesting that 
this phenomena should be further investigated in the future. 
However, this fact also clearly suggests that the NP corona is 
not subjected to any measureable protein adsorption that would 
have been seen in a size increase in our experimental time-
frame. Conclusively, we can, via this technique, confi rm that 
the P(OEGMA- co -TFEMA) exterior provides a stealthy corona 
to the NPs. This is mainly believed to be an effect of the stealth 
properties known for PEGylated polymers, however, the good 
antifouling properties of fl uorine against proteins may also 
contribute to this effect. 
 2.4 .  DOX Loading and In Vitro Release 
 The loading effi ciency of DOX into the different polymers is at 
similar level, from 70–89% (Supporting Information Table S5). heim Part. Part. Syst. Charact. 2013, 30, 381–390
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 Figure 3.  In vitro drug release of the DOX-loaded NPs. Samples were 
suspended in 4 L of PBS at 37 °C with magnetic stirring and protected 
from light. Generally, [G#2]-polymers show a higher loading effi ciency than 
[G#0]-polymers and the loading effi ciency decreases within the 
same generation when the molecular weight increases. This 
indicates that larger hydrophobic cores increase the loading 
capacity while larger hydrophilic shells decrease it. The Chol-
P(O- co -T) material, similar to [G#2]-P(O- co -T) 23k , demonstrated 
the highest capability to encapsulate DOX (ca. 88%). 
 The sizes and shapes of the DOX loaded NPs were analyzed 
by DLS (25 °C) and TEM. Results from TEM show DOX-NPs 
with sizes in the range 8.3–19.5 nm (Table  2 ; Figure  2 and Sup-
porting Information Figure S7), which is similar to the unloaded 
NPs. For DLS the three mean size parameters; intensity, 
number, and volume showed similar diameters for the different 
NPs (Table  2 and Supporting Information Figure S1). However, 
the size span of the different materials determined by DLS is far 
wider (800–1400 nm) than the diameters seen by TEM, and for 
the NPs prior to drug loading. This indicates that aggregation 
occurs after drug loading. To resolve this issue, several other 
loading methods were evaluated; with different organic solvents 
used for DOX (DMF, CHCl 3 , THF, and acetone), altered stirring 
rates, using drop-wise addition of organic solvent or aqueous 
buffer, or dialysis under sink conditions to remove free DOX. 
These methods also resulted in similar or even greater degrees 
of aggregation. Consequently, it is likely that the DOX itself, 
rather than the loading method, contributes to the aggregation, 
and we are currently exploring other anthracyline derivatives as 
target drugs for encapsulation. Additionally, one possible expla-
nation for the particle-particle interactions can be the presence 
of the fl uorinated segments in the otherwise hydrophilic PEG-
based corona of the NPs, resulting in DOX localizing partly in 
the corona upon loading. Hydrophobic interactions between 
DOX and the fl uorinated segments, in combination with strong 
 π – π interactions between DOX molecules, most likely explains 
the aggregation phenomena (especially at higher particle con-
centrations) seen from DLS to a large extent. 
 To reduce the interparticle aggregation phenomena seen 
for the DOX-loaded NPs, an additional material was synthe-
sized with the hypothesis that aggregation can be suppressed 
by introduction of proper amounts of negatively charged com-
ponents into the synthesized platforms. In this polymer, Chol-
P(OEGMA -co- MMAc -co- TFEMA), around 50% of the OEGMA 
monomers were replaced by methacrylic acid (MAAc) mono-
mers to form partly charged NPs (full experimental details 
and polymer characteristics (Table S3) are reported in the Sup-
porting Information). The NP sizes obtained from DLS and 
TEM after DOX loading of the partly charged material (Table S2 
and Figure S7) show that the interparticle aggregation seen 
for the other DOX-loaded NPs is signifi cantly suppressed. 
This indicates that introduction of negative charge into the 
hydrophilic segments of the NPs results in chain repulsion 
and prevents aggregation after DOX loading. This improved 
NP behavior, as well as the possibilities for ligand mediated tar-
geting approaches conjugated via these groups, will be further 
explored while developing the designed theranostic system for 
in vivo targeting. 
 The in vitro DOX release results for the different NPs are 
shown in  Figure  3 . All NPs show diffusion-controlled release 
profi les compared to free DOX (that diffuses out to more than 
95% in 12 h). The release kinetics of the NPs show clear core © 2013 WILEY-VCH Verlag GmPart. Part. Syst. Charact. 2013, 30, 381–390dependence, thus suggesting the DOX release can be tailored 
by the polymer design. EBiB-P(O- co -T) and Dod-P(O- co -T) 
NPs have small hydrophobic cores, and consequently exhibit 
the highest DOX release rates (ca. 65% DOX within 12 h and 
85% after 72 h), probably due to less pronounced hydrophobic 
interactions. 
 The dendritic core NPs show clear generation dependence 
from their release kinetics. The [G#0] cored NPs show a rela-
tively fast release (56% in 12 h and 76–80% in 72 h), while 
[G#2]-cored NPs have a more sustained release (about 40% in 
12 h and 61–69% in 72 h), which most likely is an effect of the 
substantially higher hydrophobicity of the [G#2] dendrimer 
core. Interestingly, the Chol-P(O- co -T) NPs shows a similar 
release profi le compared to the [G#2] core materials. This is 
believed to be a consequence of  π – π interactions between the 
ring structures of cholesterol and DOX, thus slowing down the 
drug diffusion, which has been previously observed for PS core 
NPs. [ 47 ] Conclusively, NPs with a larger hydrophobic core are 
better at keeping the drug entrapped in vitro, and cholesterol 
may be an interesting core moiety to provide controlled, sus-
tained DOX release. 
 2.5 .  Cytotoxicity Tests 
 Four different cell lines (three breast cancer and one monocyte 
cell line) showed no obvious viability depression after incu-
bation with the eight different polymers after 48 and 72 h, as 
evaluated with MTT tests ( Figure  4 A and Supporting Informa-
tion Figure S10). Pure NPs were incubated at different con-
centrations from 0.01 to 500  μ g mL −1 before DOX loading. 
At the highest concentration tested, 500  μ g mL −1 , some mate-
rials reduced the cellular viability to around 90%, however; this bH & Co. KGaA, Weinheim 385wileyonlinelibrary.com
FU
LL
 P
A
P
ER
38
www.particle-journal.com www.MaterialsViews.com
 Figure 4.  The effect of NPs and DOX-NPs on cell viability. A) Chol-P( O-co- T) and B) DOX-Chol-P( O-co- T), incubated with MCF-7, MDA-MB-231, 
MDA-MB-468, and RAW 264.7 cell lines for 48 h and 72 h. C) IC 50 of MDA-MB-231, MDA-MB-468 and RAW 264.7 cells after treatment with free DOX 
or DOX-NPs for 72 h. D) Apoptosis/necrosis of NPs and DOX-NPs for the MDA-MB-231 cell line. concentration is far above the possible in vivo concentration of 
NPs. Therefore, all NPs are considered to be non-toxic against 
the tested cancer cell lines. 
 The infl uences of free DOX and DOX-loaded NPs to the 
four cell lines were also evaluated by MTT assays (Figure  4 B 
and Supporting Information Figure S11). Considering the DOX 
concentration of each sample, the same dose in the evaluation 
(10  μ g mL −1 ) was selected as the highest concentration for the 
assays. The viability of the four different cell lines was sup-
pressed by DOX-NPs at different concentrations for both 48 
and 72 h. Generally, the viability of the cells after incubation 
with DOX-containing NPs for 72 h was lower than for 48 h. In 
addition, different cell lines showed different level of sensitivity 
to DOX. MCF-7 was the least sensitive cell line, and even at 
the highest concentration in the test (10  μ g mL −1 equivalents 
of DOX) the viability of the cells incubated with either DOX 
or DOX-NPs was still above 50%. Consequently, no accurate 
values of IC 50 of the different DOX-NPs could be obtained for 
MCF-7 cells (Supporting Information Figure S11). For the other 
cell lines, MDA-MB-231, MDA-MB-468, and RAW 267.4, IC 50 
of DOX in the different carriers at 72 h, was calculated and is 
summarized in Figure  4 C. It was found that the IC 50 of free 
DOX in MDA-MB-231 and MDA-MB-468 cells were 0.77  μ g 
mL −1 (1.33  μ M) and 0.68  μ g mL −1 (1.17  μ M), respectively, which 
are in the same range as previous published studies (MDA-MB-
231, 0.5 to 5  μ M; [ 48–50 ] MDA-MB-468, 1.2 to 8  μ M [ 51,52 ] . All mate-
rials show good carrier properties since they do not increase © 2013 WILEY-VCH Verlag G6 wileyonlinelibrary.comIC 50 values signifi cantly compared to free DOX for all three cell 
lines. MDA-MB-468 is the most sensitive cell line to DOX and 
DOX-NPs, and resulted in IC 50 values below 1.5  μ g mL −1 for 
all polymers. Further, DOX-Chol-P(O- co -T), DOX-[G#0]-P(O-
 co -T) 10k and DOX-[G#2]-P(O- co -T) 52k were found to have lower 
IC 50 than free DOX. MDA-MB-231 is less sensitive to DOX-
NPs than MDA-MB-468 cells, and all materials were found to 
have higher IC 50 compared to free DOX. This increase in IC 50 
after DOX loading into the NPs has also been seen in other 
publications. [ 50,53 ] 
 The non-toxicity of NPs and toxicity effects of DOX-NPs 
against breast cancer cell lines were further evaluated by apop-
tosis/necrosis staining and quantitative evaluations of the cells 
via fl ow activated cell sorting (FACS). None of the NPs showed 
an obvious increase of cellular apoptosis or necrosis at 24 or 48 
h of incubation with the three cell lines (Figure  4 D and Sup-
porting Information Figure S10). This indicates that the NPs 
themselves do not trigger programmed cell death. This in com-
bination with the MTT assay results strongly suggests that the 
neat NPs can be considered as non-toxic to the cancer cells. 
However, DOX-NPs were found to be highly effective against 
breast cancer cells by increasing the total percentage of dead 
cells signifi cantly. Generally, all cell lines displayed increased 
cell death after longer DOX-NPs incubation times for all mate-
rials. Interestingly, both MDA-MB-231 and MDA-MB-468 
showed increased apoptosis and decreased necrosis levels after 
48 h treatment with DOX-NPs compared to 24 h, indicating that mbH & Co. KGaA, Weinheim Part. Part. Syst. Charact. 2013, 30, 381–390
FU
LL P
A
P
ER
www.MaterialsViews.comthe apoptosis process is either slowed down or that the DOX-
NPs can alter the pathway of cell death by triggering apoptosis. 
 According to the recent review by Fadeel et al. there are two 
major apoptosis pathways: the extrinsic or death receptor-medi-
ated pathway, and the intrinsic or mitochondria-dependent 
pathway. [ 54 ] DOX can penetrate the nuclei membrane and 
intercalate with DNA, [ 55 ] and such cellular stress may trigger 
apoptosis via the intrinsic pathway. [ 56–58 ] However, we have not 
investigated the mechanism of apoptosis in detail in this man-
uscript, as the process and the signaling pathways leading to 
apoptosis are out of our scope and requires a dedicated effort by 
experts. [ 59,60 ] Further, the longer incubation times were found to 
result in higher death rates (Figure  4 D and Supporting Infor-
mation Figure S12), which is consistent with the MTT results 
that show a reduced viability of cancer cells after incubation 
with DOX-NPs for 72 h (Supporting Information Figure S11) 
compared to 48 h (data not shown). A lower apoptosis level was 
found by DOX-NPs in MCF-7 compared to the other two breast 
cancer cell lines. This suggests that MCF-7 cells might be able 
to resist DOX to some extent, which is consistent with the MTT 
results. 
 2.6 .  Cellular Uptake and Localization of NPs and DOX-NPs 
 Cellular uptake and localization of DOX and DOX-NPs was 
evaluated by FACS and confocal microscopy, respectively. The 
position movements of MDA-MB-468 cells, indicating DOX 
uptake after 24 and 48 h, are shown in Supporting Informa-
tion Figure S13. For this cell line, the uptake of free DOX was 
found to be signifi cantly ( p < 0.05) higher than DOX-NPs after 
48 h, while for the other cell lines no obvious difference was 
observed (Supporting Information Figure S14A). Furthermore, 
the cellular uptake of fl uorescently labeled NPs, FITC-Chol-P(O-
 co -T) and FITC-[G#0]-P(O- co -T) 28k , was analyzed and compared 
to the negative control. The results in Supporting Information 
Figure S13E,K and F,L of cells treated with FITC-Chol-P(O-
 co -T) and FITC-[G#0]-P(O- co -T) 28k confi rms the NP uptake. 
For MCF-7 cells both time and NP dependent uptake increase 
was observed ( p < 0.001), while for the MDA-MB-468 cells the 
uptake of FITC-[G#0]-P(O- co -T) 28k was signifi cantly higher com-
pared to FITC-Chol-P(O- co -T) ( p < 0.001) (Supporting Informa-
tion Figure S14B). 
 To further evaluate the drug delivery effi cacy of the NPs, the 
distribution of DOX and NPs were studied in cells. DOX-[G#0]-
P(O- co -T) 28k and DOX-Chol-P(O- co -T) NPs were incubated in 
cells for different time periods, and the same dose of free DOX 
was used as positive control. DOX-NPs favorably distributed 
similarly as free DOX in MDA-MB-231 cells ( Figure  5 ). Both 
free DOX, and DOX released from the NPs were easily observed 
in the cells, concentrated in the nuclei, which is consistent with 
earlier studies. [ 61,62 ] In addition, the amount of DOX in the 
nuclei increased after 48 h incubation compared to 4 h. This 
indicates that encapsulation by the NPs does not prevent DOX 
from being released and penetrating into the nuclei. Similar 
localization patterns were also found in RAW 246.7 cells, which 
is not a breast cancer cell line (Supporting Information Figure 
S15). This suggests that the effi cacy of our NPs may also be 
applicable for other cancer types. © 2013 WILEY-VCH Verlag Part. Part. Syst. Charact. 2013, 30, 381–390www.particle-journal.com
 A localization study of the NPs was performed by incubating 
FITC-[G#0]-P(O -co- T) 28k NPs with the two cell lines for different 
periods of time, and images were obtained using confocal 
microscopy. All cell lines were able to internalize FITC-[G#0]-
P(O- co -T) 28k NPs after 48 h of incubation. NPs were mainly 
found in the cytoplasm and concentrated at the surroundings 
of the nuclei with a minority overlapping with the nuclei (Sup-
porting Information Figure S16). Unlike DOX, which is mainly 
concentrated in the nuclei, the NPs are considered to have very 
low penetration through the nuclei membrane due to their 
large size. The uptake rate of the NPs varied between the two 
cell lines, where the RAW 246.7 cells demonstrated the fastest 
uptake. 
 2.7 .  In Vitro  19 F-MRI Studies 
 The fl uorinated NPs were further evaluated as contrast agents 
for  19 F-MRI. The measurements were conducted by loading the 
NPs (190-970  μ M in PBS) into 6 mm diameter plastic syringes. 
Depending on the molecular weight of the different polymers, 
fl uorine concentrations between 23–56 mM was achieved. The 
MRI phantoms (the cross-section of a syringe) seen in  Figure 6 , 
showing that all the materials exhibited very good imaging 
capability. In only 10 min scanning time (32 scans), signal-to-
noise (SNR) ratios of 7–16 were achieved for all the NPs. This 
is most likely an effect of the high fl uorine concentration of the 
polymers, as well as favorable chain mobility in the hydrophilic 
segments. However, for future practical use in vivo, the local 
concentration of the NPs must be suffi cient to ensure high 
enough concentration for effective imaging. Such local concen-
tration enhancement can be achieved via either passive (EPR 
effect) or active targeting measures (small molecular, peptide, 
or antibody based tissue specifi c ligand targeting). [ 63,64 ] As men-
tioned earlier, introduction of acrylic acid segments to the poly-
mers will provide potential handles for such functionalization 
and is currently under investigation. 
 Recently results published by Matsuda et al. [ 31 ] reveals ben-
efi cial  19 F-imaging properties of statistical copolymers of 
2,2,3,3-tetrafl uoropropyl methacrylate and methyl acrylate 
(PTFPMA -co- PMA) grafted from PAMAM dendrimer cores 
due to increased fl uorine mobility gained by the star-like archi-
tecture. The synthesized NPs in this study behave in a similar 
fashion, however; benefi ts from the combination of the more 
physiologically inert POEGMA sequences and biocompatible 
bis-MPA structure, in comparison to the charged and toxic 
PAMAM dendrimer. [ 65 ] This suggests that statistical P(OEGMA-
 co -TFEMA) copolymers may be an attractive approach to intro-
duce diagnostic functions to drug delivery platforms. 
 3 .  Conclusions 
 Fluorinated NPs were successfully prepared by self-assembly of 
both linear and star-shaped block copolymers. Incorporation of 
fl uorinated segments allow the NPs to be detected by  19 F-MRI, 
and the hydrophobic cores are able to encapsulate DOX, and 
generate thereby a versatile theranostic system. The designed 
core-shell type NPs are around 10 nm in size and allow for GmbH & Co. KGaA, Weinheim 387wileyonlinelibrary.com
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 Figure 5.  Localization of DOX for the MDA-MB-231 breast cancer cell line. The nuclei of the cells are stained by DAPI (blue), and DOX (red). Cells were 
treated with 5  μ g mL −1 of free DOX, DOX-[G#0]-P(O- co -T) 28k NPs, or DOX-Chol-P(O- co -T) NPs for 4 h and 48 h. Scale bar = 20  μ m. 
 Figure 6.  19 F-MRI phantoms of the polymers in PBS (10 mg mL −1 ) received after 10 min (32 scans). A) EBiB-P(O- co -T), B) Dod-P(O- co -T), C) Chol-P(O-
 co -T), D) [G#0]-P(O- co- T) 10k , E) [G#0]-P(O- co -T) 28k , F) [G#2]-P(O- co -T) 23k , G) [G#2]-P(O- co -T) 36k , and H) [G#2]-P(O- co -T) 52k . 
Part. Part. Syst. Charact. 2013, 30, 381–390
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NPs show interparticle aggregation, however, this is proved to 
be signifi cantly reduced by incorporation of negatively charged 
segments into the polymers. The DOX release kinetics of the 
nanocarriers show clear core dependence, thus suggesting that 
the release from the formed NPs can be tuned by the macro-
molecular architecture. Further,  19 F-NMR diffusion studies 
prove that the NPs are not subjected to any detectable protein 
adsorption in plasma, thus indicating a stealthy appearance due 
to the exterior POEGMA segments. Confocal studies suggest 
that the NPs can be taken up by breast cancer cells and deliver 
the drug into the cell nuclei. In addition, neat NPs proved to 
be non-toxic to breast cancer cells by apoptosis and MTT tests, 
while DOX-loaded NPs showed a dose-dependent toxicity. Con-
clusively, the designed fl uorinated NPs show controllable drug 
release kinetics, are detectable by  19 F-MRI, and are non-toxic to 
breast cancer cells; they are therefore a promising approach to 
design a theranostic delivery system. 
 4 .  Experimental Section 
 Materials : Details for all reagents are provided in the Supporting 
Information. 
 Synthesis and Characterization :  D etails of the preparation of the 
polymers and instruments utilized for characterization ( 1 H- and 
 13 C-NMR, SEC, MALDI-TOF, DLS, TEM, CMC) of the fl uorinated 
copolymers are reported in the Supporting Information, as well as the 
instrumentation for  19 F-NMR diffusion,  19 F-MRI, FACS, microscopy, etc. 
 Doxorubicin Loading : DOX stock solution was prepared by dissolving 
DOX and TEA (1:3 mol eq) in CH 2 Cl 2 (1 mg mL −1 ). The stock solution 
(1 mL) was diluted with CH 2 Cl 2 (1 mL) and mixed with a phosphate 
buffer saline (PBS) solution of NPs (4 mL, 1.25 mg mL −1 ). The mixture 
was stirred overnight at 100 rpm in order to evaporate the organic 
solvent. Free DOX was removed by spin fi ltration with a MWCO of 
3 kDa by refi lling PBS every 5 min. The concentration of DOX in NPs was 
measured by comparing UV absorbance at 490 nm, of samples diluted 
with DMF:H 2 O (4:1) to a standard curve (fi ve replicates). 
 In Vitro Drug Release : DOX or DOX-NPs solutions were transferred 
into dialysis cassettes (MWCO 3500, Slide-A-Lyzer, Thermo) containing 
3 mL PBS for each sample. Cassettes were suspended in 4 L of PBS. 
Aliquots from the cassettes were collected (triplicates of 10  μ L each) at 
the following time intervals: 0, 2, 4, 8, 12, 24, 48, and 72 h. Thereafter, 
the samples were transferred into fl uorescence plates, containing 100  μ L 
DMF:H 2 O (4:1) and diluted with 100  μ L PBS. The fl uorescence intensity 
of samples was determined using a plate reader (BioTek Synergy MX) at 
wavelength 480/600 (excitation/emission) nm. [ 66 ] 
 19 F-NMR and  19 F-NMR Diffusion :  19 F-NMR was employed to determine 
longitudinal ( T 1 ) and transverse ( T 2 ) relaxation times, and self-diffusion 
of the molecules for size determination in different media. For all  19 F 
NMR studies, the different samples were dissolved at 0.5% (w/w) in the 
given solvents. The measurements were performed at 37 (± 0.1) °C on 
a Bruker 600 MHz Avance spectrometer operating at 564 MHz for  19 F, 
equipped with a Diff30 diffusion probe. To collect  T 1 data an inversion 
recovery pulse sequence was used and for  T 2 a CPMG pulse sequence 
was accumulated. Self-diffusion measurements were performed using 
NMR diffusometry (NMRd). [ 67,68 ] Additional information about the NMR 
diffusion studies can be found in the Supporting Information as well as 
detailed instrumentation details and supplemental physiochemical and 
in vitro results. 
 Cellular-Based Tests : Human breast cell lines MDA-MB-231, MDA-
MB-468 cells and MCF-7 and mouse monocyte macrophage cell line 
RAW 264.7 were cultured in DMEM (pH 7.4) containing 10% (v/v) 
FBS, 100 U mL −1 penicillin, and 2 mM glutamine solution at 37 °C in 
a humidifi ed atmosphere with 5% CO 2 . The three breast cancer cells © 2013 WILEY-VCH Verlag GPart. Part. Syst. Charact. 2013, 30, 381–390www.particle-journal.com
were harvested by trypsin while RAW 264.7 was harvested by scraping. 
MTT assay was preceded for cellular viability tests. The four different 
cells were separately seeded into 96-well plates, and the concentration 
was adjusted to 5 × 10 4 cells per well (in 100  μ L DMEM) and fi nally 
cultured for 24 h. The medium was removed and the plate was refi lled 
with 100  μ L of fresh medium containing various concentrations of the 
NPs, DOX-NPs, and DOX (4 parallel wells for each concentration). The 
cells were incubated for another 48 h or 72 h before 10  μ L MTT solution 
(5 mg mL −1 ) was added to each well. Thereafter, the cells were incubated 
for additional 4 h, and 100  μ L SDS solutions (10%) were added to 
each well. The absorbance was measured after 18 h in a plate reader 
at 570 nm. [ 6 ] The details of other cell based experiments, including 
apoptosis/necrosis, uptake and localization studies are reported in the 
Supporting Information. 
 Statistical Analysis : Dynamic light scattering, cell viability tests, drug 
release and uptake studies are presented as mean values with standard 
deviation (SD). For the uptake studies statistical analysis was performed 
with the Student’s t-test and  p < 0.001 was considered signifi cant. The 
drug release curve and IC 50 curves were plotted in KaleidaGraph v4.1 
(Synergy Software, Reading, PA). 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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